Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells

Toxicology in Vitro

Volumn 28, Issue 7, 2014, Pages 1259-1273

  Jendželovská, Zuzana ^a   Jendželovský, Rastislav ^a   Hilovská, Lucia ^a   Koval, Ján ^a   Mikeš, Jaromír ^a   Fedoročko, Peter ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

BCRP; Cisplatin; Hypericin; Mitoxantrone; MRP; St. John's wort

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; HYPERICIN; MITOXANTRONE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; PERYLENE; TUMOR PROTEIN;

ARTICLE; CELL CYCLE ARREST; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; HYPERICUM PERFORATUM; MOLECULAR DYNAMICS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANALOGS AND DERIVATIVES; CELL DEATH; DRUG EFFECTS; DRUG INTERACTION; GENETICS; HYPERICUM; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; DRUG INTERACTIONS; HUMANS; HYPERICUM; MITOXANTRONE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PERYLENE; RNA, MESSENGER;

EID: 84904385632     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2014.06.011     Document Type: Article

References (51)

1. An G., Morris M.E. Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro. Pharm. Res. 2010, 27:1296-1308.
2. Borrelli F., Izzo A.A. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J. 2009, 11:710-727.
3. Butterweck V., Schmidt M. St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien. Med. Wochenschr. 2007, 157:356-361.
4. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
5. Clingen P.H., Wu J.Y., Miller J., Mistry N., Chin F., Wynne P., Prise K.M., Hartley J.A. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem. Pharmacol. 2008, 76:19-27.
6. Di Y.M., Li C.G., Xue C.C., Zhou S.F. Clinical drugs that interact with St. John's wort and implication in drug development. Curr. Pharm. Des. 2008, 14:1723-1742.
7. Frye R.F., Fitzgerald S.M., Lagattuta T.F., Hruska M.W., Egorin M.J. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin. Pharmacol. Ther. 2004, 76:323-329.
8. Godtel-Armbrust U., Metzger A., Kroll U., Kelber O., Wojnowski L. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort. Naunyn Schmiedebergs Arch. Pharmacol. 2007, 375:377-382.
9. Goey A.K., Meijerman I., Rosing H., Marchetti S., Mergui-Roelvink M., Keessen M., Burgers J.A., Beijnen J.H., Schellens J.H. The effect of St John's wort on the pharmacokinetics of docetaxel. Clin. Pharmacokinet. 2014, 53:103-110.
10. Gutmann H., Poller B., Buter K.B., Pfrunder A., Schaffner W., Drewe J. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?. Planta Med. 2006, 72:685-690.
11. Haslam I.S., Jones K., Coleman T., Simmons N.L. Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). Biochem. Pharmacol. 2008, 76:850-861.
12. Hinoshita E., Uchiumi T., Taguchi K., Kinukawa N., Tsuneyoshi M., Maehara Y., Sugimachi K., Kuwano M. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin. Cancer Res. 2000, 6:2401-2407.
13. Hollo Z., Homolya L., Hegedus T., Sarkadi B. Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett. 1996, 383:99-104.
14. Huang X., Okafuji M., Traganos F., Luther E., Holden E., Darzynkiewicz Z. Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin. Cytometry A 2004, 58:99-110.
15. Iida T., Kijima H., Urata Y., Goto S., Ihara Y., Oka M., Kohno S., Scanlon K.J., Kondo T. Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001, 8:803-814.
16. Ikuta K., Takemura K., Sasaki K., Kihara M., Nishimura M., Ueda N., Naito S., Lee E., Shimizu E., Yamauchi A. Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol. Pharm. Bull. 2005, 28:707-712.
17. Imai Y., Tsukahara S., Asada S., Sugimoto Y. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res. 2004, 64:4346-4352.
18. Jendzelovsky R., Mikes J., Koval J., Soucek K., Prochazkova J., Kello M., Sackova V., Hofmanova J., Kozubik A., Fedorocko P. Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem. Photobiol. Sci. 2009, 8:1716-1723.
19. Jin J., Shahi S., Kang H.K., van Veen H.W., Fan T.P. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem. Biophys. Res. Commun. 2006, 345:1308-1314.
20. Kleban J., Mikes J., Szilardiova B., Koval J., Sackova V., Solar P., Horvath V., Hofmanova J., Kozubik A., Fedorocko P. Modulation of hypericin photodynamic therapy by pretreatment with 12 various inhibitors of arachidonic acid metabolism in colon adenocarcinoma HT-29 cells. Photochem. Photobiol. 2007, 83:1174-1185.
21. Koberle B., Tomicic M.T., Usanova S., Kaina B. Cisplatin resistance: preclinical findings and clinical implications. Biochim. Biophys. Acta 2010, 1806:172-182.
22. Komoroski B.J., Zhang S., Cai H., Hutzler J.M., Frye R., Tracy T.S., Strom S.C., Lehmann T., Ang C.Y., Cui Y.Y., Venkataramanan R. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab. Dispos. 2004, 32:512-518.
23. Korita P.V., Wakai T., Shirai Y., Matsuda Y., Sakata J., Takamura M., Yano M., Sanpei A., Aoyagi Y., Hatakeyama K., Ajioka Y. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol. Rep. 2010, 23:965-972.
24. Ma J.J., Chen B.L., Xin X.Y. Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene. Arch. Gynecol. Obstet. 2009, 279:149-157.
25. Ma M.T., He M., Wang Y., Jiao X.Y., Zhao L., Bai X.F., Yu Z.J., Wu H.Z., Sun M.L., Song Z.G., Wei M.J. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett. 2013, 339:107-115.
26. Materna V., Stege A., Surowiak P., Priebsch A., Lage H. RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem. Biophys. Res. Commun. 2006, 348:153-157.
27. Mathijssen R.H., Verweij J., de Bruijn P., Loos W.J., Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J. Natl Cancer Inst. 2002, 94:1247-1249.
28. Nagata J., Kijima H., Hatanaka H., Asai S., Miyachi H., Takagi A., Miwa T., Mine T., Yamazaki H., Nakamura M., Kondo T., Scanlon K.J., Ueyama Y. Reversal of cisplatin and multidrug resistance by ribozyme-mediated glutathione suppression. Biochem. Biophys. Res. Commun. 2001, 286:406-413.
29. Obach R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J. Pharmacol. Exp. Ther. 2000, 294:88-95.
30. Olive P.L., Banath J.P. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin. Cytom. 2009, 76:79-90.
31. Ott M., Huls M., Cornelius M.G., Fricker G. St. John's Wort constituents modulate P-glycoprotein transport activity at the blood-brain barrier. Pharm. Res. 2010, 27:811-822.
32. Ozvegy-Laczka C., Hegedus T., Varady G., Ujhelly O., Schuetz J.D., Varadi A., Keri G., Orfi L., Nemet K., Sarkadi B. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 2004, 65:1485-1495.
33. Patel J., Buddha B., Dey S., Pal D., Mitra A.K. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am. J. Ther. 2004, 11:262-277.
34. Perego P., De Cesare M., De Isabella P., Carenini N., Beggiolin G., Pezzoni G., Palumbo M., Tartaglia L., Pratesi G., Pisano C., Carminati P., Scheffer G.L., Zunino F. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res. 2001, 61:6034-6037.
35. Perloff M.D., von Moltke L.L., Stormer E., Shader R.I., Greenblatt D.J. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br. J. Pharmacol. 2001, 134:1601-1608.
36. Prochazkova J., Kubala L., Kotasova H., Gudernova I., Sramkova Z., Pekarova M., Sarkadi B., Pachernik J. ABC transporters affect the detection of intracellular oxidants by fluorescent probes. Free Radic. Res. 2011, 45:779-787.
37. Ross D.D., Yang W., Abruzzo L.V., Dalton W.S., Schneider E., Lage H., Dietel M., Greenberger L., Cole S.P., Doyle L.A. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl Cancer Inst. 1999, 91:429-433.
38. Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int. Clin. Psychopharmacol. 2000, 15:61-68.
39. Sharp S.Y., Smith V., Hobbs S., Kelland L.R. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. Br. J. Cancer 1998, 78:175-180.
40. Shibayama Y., Kawachi A., Onimaru S., Tokunaga J., Ikeda R., Nishida K., Kuchiiwa S., Nakagawa S., Takamura N., Motoya T., Takeda Y., Yamada K. Effect of pre-treatment with St John's Wort on nephrotoxicity of cisplatin in rats. Life Sci. 2007, 81:103-108.
41. Smith P., Bullock J.M., Booker B.M., Haas C.E., Berenson C.S., Jusko W.J. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004, 24:1508-1514.
42. Solomon D., Ford E., Adams J., Graves N. Potential of St John's Wort for the treatment of depression: the economic perspective. Aust. N. Z. J. Psychiatry 2011, 45:123-130.
43. Surowiak P., Materna V., Kaplenko I., Spaczynski M., Dolinska-Krajewska B., Gebarowska E., Dietel M., Zabel M., Lage H. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin. Cancer Res. 2006, 12:7149-7158.
44. Tian R., Koyabu N., Morimoto S., Shoyama Y., Ohtani H., Sawada Y. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line. Drug Metab. Dispos. 2005, 33:547-554.
45. Wada A., Sakaeda T., Takara K., Hirai M., Kimura T., Ohmoto N., Zhou J., Nakamura T., Kobayashi H., Okamura N., Yagami T., Okumura K. Effects of St John's wort and hypericin on cytotoxicity of anticancer drugs. Drug Metab. Pharmacokinet. 2002, 17:467-474.
46. Wang E.J., Barecki-Roach M., Johnson W.W. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin. J. Pharm. Pharmacol. 2004, 56:123-128.
47. Wang W., Sun Y.P., Huang X.Z., He M., Chen Y.Y., Shi G.Y., Li H., Yi J., Wang J. Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem. Pharmacol. 2010, 79:1134-1140.
48. Wang H., Li X., Chen T., Wang W., Liu Q., Li H., Yi J., Wang J. Mechanisms of verapamil-enhanced chemosensitivity of gallbladder cancer cells to platinum drugs: glutathione reduction and MRP1 downregulation. Oncol. Rep. 2013, 29:676-684.
49. Yamasaki M., Makino T., Masuzawa T., Kurokawa Y., Miyata H., Takiguchi S., Nakajima K., Fujiwara Y., Matsuura N., Mori M., Doki Y. Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br. J. Cancer 2011, 104:707-713.
50. Zhang F., Throm S.L., Murley L.L., Miller L.A., Steven Zatechka D., Kiplin Guy R., Kennedy R., Stewart C.F. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochem. Pharmacol. 2011, 82:24-34.
51. Zhou Y.T., Li K., Tian H. Effects of vinorelbine on cisplatin resistance reversal in human lung cancer A549/DDP cells. Asian Pac. J. Cancer Prev. 2013, 14:4635-4639.